Skip to content
DataLookout
Menu

FEASTNCT07898839

FEAST and HOPE: Redox PSC Pilot Study

StatusNot Yet Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Change in Serum Alkaline Phosphatase (ALP) From Baseline to Week 16
Timeframe: Baseline (Week 0) and Week 16
Percentage of Participants With ≥50% Reduction in Serum ALP at Week 16
Timeframe: Baseline (Week 0) and Week 16

Secondary (4)

Change in Liver Biochemistry From Baseline to Week 16
Change in Pro-peptide of Type III Collagen (PRO-C3) From Baseline to Week 16
Change in Enhanced Liver Fibrosis (ELF) Score From Baseline to Week 16
Change in LMR Inflammatory Panel Markers From Baseline to Weeks 8 and 16

Arms and interventions

Study Diet Plus ALA, NAC, NR, and MetforminExperimental

Single-arm, open-label. All participants follow a study diet and take four oral agents targeting disulfidptosis for approximately 16 weeks (Baseline through Week 16). Study diet: guided by study dietitians, with grocery support and meal photo logging via the MetaBite app. Study agents: alpha-lipoic acid (ALA) 600 mg once daily in Week 0, then 600 mg twice daily from Week 1; N-acetylcysteine (NAC); nicotinamide riboside (NR) 500 mg twice daily; and metformin extended-release, with doses titrated over the initial weeks per protocol. Enrollment is stratified by inflammatory bowel disease (IBD) status. Study agents may be withdrawn sequentially per the protocol-defined ALP management plan.

Dietary supplements: N-Acetyl Cysteine (NAC), Alpha-Lipoic Acid (ALA), Nicotinamide Riboside (NR)

Drugs: Metformin Hydrochloride Extended-Release Tablets

Other: Study Diet